Karen L. Zaderej - Mar 16, 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
CEO, Director
Signature
/s/ Karen Zaderej
Stock symbol
AXGN
Transactions as of
Mar 16, 2022
Transactions value $
$0
Form type
4
Date filed
3/18/2022, 04:12 PM
Previous filing
Feb 17, 2022
Next filing
Jul 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $0 +26K +2.76% $0.00 966K Mar 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Restricted Stock Units Options Exercise $0 -26K -50% $0.00 26K Mar 16, 2022 Common Stock 26K Direct F2, F3
transaction AXGN Restricted Stock Units Award $0 +170K $0.00 170K Mar 16, 2022 Common Stock 170K Direct F2, F4
transaction AXGN Employee Stock Option (right to purchase) Award $0 +317K $0.00 317K Mar 16, 2022 Common Stock 317K $10.25 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This reflects the number of restricted stock units that became vested as of March 16, 2022.
F2 Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F3 All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F4 All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5 The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.
F6 All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.